Shares in biotechnology firm Oxford BioDynamics jumped eight per cent yesterday (Tuesday) after the firm announced its long-awaited inhibitor response test was being made available to UK doctors.
The first-of-its-kind EpiSwitch CiRT blood test predicts the likelihood of a cancer patient’s response to the widely used class of therapeutics.
Using a routine blood test, rather than an invasive biopsy, CiRT provides fast, personalised guidance for a physician on expected efficacy, enabling a more considered decision whether to begin or continue treatment.
The test has demonstrated best-in-class performance, with high sensitivity (93 per cent), specificity (82 per cent), and accuracy (85 per cent), across several therapies from multiple pharmaceutical companies and more than 15 key oncological indications, including melanoma and lung cancer.
Expansion to the UK follows encouraging early uptake by early adopters of EpiSwitch CiRT in the US where it was first launched in February this year.